Results 181 to 190 of about 809,292 (357)

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK‐pot Collaboration

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To develop, externally validate, and simplify a machine‐learning (ML) model to predict remission between six and 24 months in rheumatoid arthritis (RA) patients initiating TNF inhibitors, JAK inhibitors, IL‐6 inhibitors, abatacept, or rituximab, using data from 11 international registries in the JAK‐pot collaboration.
Zubeyir Salis   +22 more
wiley   +1 more source

Body donor programs in Australia and New Zealand: Current status and future opportunities

open access: yesAnatomical Sciences Education, Volume 18, Issue 3, Page 301-328, March 2025.
Abstract Body donation is critical to anatomy study in Australia and New Zealand. Annually, more than 10,000 students, anatomists, researchers, and clinicians access tissue donated by local consented donors through university‐based body donation programs. However, little research has been published about their operations.
Rebekah A. Jenkin, Kevin A. Keay
wiley   +1 more source

Home - About - Disclaimer - Privacy